Heart transplantation. Approaching a new century

Texas Heart Institute Journal

Volumn 26, Issue 1, 1999, Pages 60-70

  Radovančević, Branislav ^a   Frazier, O H ^a  

^a TEXAS HEART INSTITUTE   (United States)

Author keywords

Coronary disease transplantation; Graft rejection; Heart failure, congestive; Heart transplantation; Immunosuppression; Immunosuppressive agents

Indexed keywords

ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; HEART FAILURE; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; POSTOPERATIVE COMPLICATION;

HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; PROGNOSIS; SURVIVAL RATE;

EID: 0344197629     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report - 1998. J Heart Lung Transplant 1998;17:656-68.
2. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429-35.
3. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation 1994;89:1632-42.
4. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-86.
5. Benedict CR, Weiner DH, Johnstone ED, Bourassa MG, Ghali JK, Nicklas J, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 1993;22(4 Suppl A):146A-53A.
6. Stevenson LW, Steimle AE, Fonarow G, Kermani D, Hamilton MA, Moriguchi JD, et al. Improvement in exercise capacity of candidates awaiting heart transplantation. J Am Coll Cardiol 1995;25:163-70.
7. Stevenson LW. Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. J Heart Lung Transplant 1991;10:468-76.
8. Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier VL, et al. Multicenter clinical evaluation of the Heart-Mate 1000 IP left ventricular assist device. Ann Thorac Surg 1992;53:1080-90.
9. 1997 Annual Report of the U.S. Scientific Registry of Transplant Recipients and The Organ Procurement and Transplant Network - Transplant Data 1988-1996. UNOS, Richmond, VA, and the Division of Transplantation, Office of Special Programs, Health Resources and Services Administration, U.S. Department of Health and Human Services, Rockville, MD.
10. Laks H, Scholl FG, Drinkwater DC, Blitz A, Hamilton M, Moriguchi J, et al. The alternate recipient list for heart transplantation: does it work? J Heart Lung Transplant 1997;16: 735-42.
11. Chou SW, Norman DJ. The influence of donor factors other than serologic status on transmission of cytomegalovirus to transplant recipients. Transplantation 1988;46:89-93.
12. Lake KD, Smith CI, LaForest SK, Allen J, Pritzker MR, Emery RW. Policies regarding the transplantation of hepatitis C-positive candidates and donor organs. J Heart Lung Transplant 1997;16:917-21.
13. Nakatani T, Frazier OH, Lammermeier DE, Macris MP, Radovančević B. Heterotopic cardiac transplantation: a reliable option for a select group of high-risk patients. J Heart Transplant 1989;8:40-7.
14. Jeevanandam V, Mather P, Furukawa S, Todd B, Regillo T, Bove AA, et al. Adult orthotopic heart transplantation using undersized pediatric donor hearts. Technique and postoperative management. Circulation 1994;90(5 Pt 2):II74-7.
15. Lockett MF. Dangerous effects of isoprenaline in myocardial failure. Lancet 1965;2:104-6.
16. Dibner-Dunlap ME, Thames MD. A simplified technique for the production of heart failure in the dog by rapid ventricular pacing. Am J Med Sci 1990;300:288-90.
17. Kerman R, Susskind B, Buelow R, et al. Prognostic value of pretransplant serum screening of 493 renal and 130 cardiac recipients: prediction of rejection and graft loss. Proc Am Soc Transpl Surg 1996:181.
18. Karavolias G, Mitchell A. Yacoub M. Prognostic value of accelerated coronary artery disease after orthotopic cardiac transplantation [abstract]. Eur Heart J 1993;14(Suppl):343.
19. Wildhirt SM, Schulze C, Weis M, Conrad N, Rieder G, Boehm H et al. University of Wisconsin versus Celsior preservation solutions: evidence for myocardial stunning, endothelial dysfunction and induction of nitric oxide synthase and endothelin after heart transplantation. In: Transplant98 Book of Abstracts. XVII World Congress of The Transplantation Society, July 12-17, 1998. Montreal: 1998:21.
20. Jeevanandam V, Todd B, Regillo T, Hellman S, Eldridge C, McClurken J. Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy. J Heart Lung Transplant 1994;13:681-7.
21. Nishimura M, Radovančević B, Springer W, Massin EK, Frazier OH. Donor heart ischemic time is a risk factor for early manifestation of allograft coronary artery disease. J Am Coll Cardiol 1997;29(2 Suppl A):402A.
22. Lower RR, Shumway NE. Studies of the orthotopic homotransplantation of the canine heart. Surg Forum 1960;11:18-9.
23. Dreyfus G, Jebara V, Mihaileanu S, Carpentier AF. Total orthotopic heart transplantation: an alternative to the standard technique. Ann Thorac Surg 1991;52:1181-4.
24. Barnard CN, Losman JG. Left ventricular bypass. S Afr Med J 1975;49:303-12.
25. Novitsky D, Cooper DK, Barnard CN. The surgical technique of heterotopic heart transplantation. Ann Thorac Surg 1983; 36:476-82.
26. Booth JV, Wheeldon DR, Ghosh S. Anesthetic management, including cardiopulmonary bypass. In: Cooper DKC, Miller LW, Patterson GA. The transplantation and replacement of thoracic organs. United Kingdom: Kluwer Academic Publishers, 1996:195-7.
27. Auler JO Jr, Carmona MJ, Bocchi EA, Bacal F, Fiorelli AI, Stolf NA, et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant 1996;15:443-50.
28. Nakatani T, Radovančević B, Frazier OH. Right heart assist for acute right ventricular failure after orthotopic heart transplantation. ASAIO Trans 1987;33:695-8.
29. Radovančević B. Radovančević R, Bracey A, Vaughn W, McAllister H, Frazier OH. Factors influencing bleeding and blood use after heart transplantation. J Heart Lung Transplant 1994;13(1 Part 2):S56.
30. Royston D. Aprotinin therapy in heart and heart-lung transplantation. J Heart Lung Transplant 1993;12(1 Pt 1):S19-25.
31. Bracey A, Radovančević R, Radovančević B, Chen RHT, Vaughn WK, McAllister H Jr, et al. Decreased bleeding and blood requirements during heart transplantation with the use of hemostatic drugs [abstract]. Transfusion 1995;35 (Suppl):63S.
32. Cooper DKC, Lidsky NM. Immediate postoperative care and potential complications. In: Cooper DKC, Miller LW, Patterson GA. The transplantation and replacement of thoracic organs. United Kingdom: Kluwer Academic Publishers, 1996: 221-7.
33. Armitage JM, Kormos RL, Fung J, Starzl TE. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. Transplant Proc 1991;23:3054-7.
34. Taylor DO, Barr ML, Radovančević B, Mentzer RM Jr, Smart FW, Tolman DE, et al. A comparison of tacrolimus- and cyclosporine-based immunosuppression in cardiac transplantation. J Heart Lung Transplant 1997;16:72.
35. Roth D, Colona J, Burke GW, Ciancio G, Esquenazi V, Miller J. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation 1998;65:248-52.
36. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998;66: 507-515.
37. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK 3rd, Boehmer JP, Brozena SC, et al. Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998;17:744-53.
38. Radovančević B, Bologna MT, Torre-Amione G, Sooudi SK, Durand JB. Noon GP, et al. Analysis of outcomes in elderly heart transplant recipients: can we tailor immunosuppressive therapy? J Heart Lung Transplant 1998;17:102.
39. Radovančević B, Bologna M, Bracey A, Radovančević R, Kimball P, McAllister H, and Kerman R. Humoral rejection following heart transplant: plasma exchange as a therapeutic option. In: Transplant98 Book of Abstracts. XVII World Congress of The Transplantation Society, July 12-17, 1998. Montreal: 1998: 172.
40. Eisen H, Bourge R, Hershberger R, Keller A, Radovančević B, Mehta N, et al. Noninvasive rejection monitoring of heart transplants using high-resolution pacemaker telemetry -initial US multicenter results [abstract]. Pacing Clin Electrophysiol 1998;21:814.
41. McGhie AI, Radovančević B, Moore W, Capek P, Clubb F, Kasi L, et al. Non-invasive detection of cardiac allograft rejection: preliminary findings using in vivo imaging with radiolabeled monoclonal antibody to ICAM-1 and MHC Class II antigen [abstract]. J Nucl Med 1995;36(5 Suppl):102P.
42. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990;9:587-93.
43. McAllister HA Jr, Schnee MJM, Radovančević B, Frazier OH. A system for grading cardiac allograft rejection. Tex Heart Inst J 1986;13:1-3.
44. Steinmuller DR. FK506 and organ transplantation. Boca Raton, Fla: CRC Press, 1994.
45. Kirklin JK, Bourge RC, Naftel DC, Morrow WR, Deierhoi MH, Kauffman RS, et al. Treatment of recurrent heart rejection with mycophenolate mofetil (RS-61443): initial clinical experience. J Heart Lung Transplant 1994; 13:444-50.
46. Costanzo-Nordin MR, Grusk BB, Silver MA, Sobotka PA, Winters GL, O'Connell JB, et al. Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation 1988; 78(5 Pt 2):III 47-57.
47. Salter MM, Kirklin JK, Bourge RC, Naftel DC, White-Williams C, Tarkka M, et al. Total lymphoid irradiation in the treatment of early or recurrent heart rejection. J Heart Lung Transplant 1992; 11:902-12.
48. Evans MA, Schomberg PJ, Rodeheffer RJ, Katzmann JA, Schnell WA Jr, Tazelaar HD, et al. Total lymphoid irradiation: a novel and successful therapy for resistant cardiac allograft rejection. Mayo Clin Proc 1992; 67:785-90.
49. Hunt SA, Strober S, Hoppe RT, Stinson EB. Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J Heart Lung Transplant 1991; 10:211-6.
50. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, Johnson MR, Mullen GM, Heroux AL, et al. Successful treatment of heart transplant with photopheresis. Transplantation 1992; 53:808-15.
51. Barr ML, Meiser BM, Eisen HJ, Roberts RF, Livi U, Dall'Amico R, et al. Photopheresis for the prevention of rejection in cardiac transplantation. N Engl J Med 1998;339(24):1744-51.
52. Baldwin RT, Radovančević B, Sweeney MS, Duncan JM, Frazier OH. Bacterial mediastinitis after heart transplantation. 1992;11(3 Pt 1):545-9.
53. Andreone PA, Olivari MT, Elick B, Arentzen CE, Sibley RK, Bolman RM, et al. Reduction of infectious complications following heart transplantation with triple-drug immunotherapy. J Heart Transplant 1986;5:13-9.
54. Rubin RH, Tolkoff-Rubin NE. Infection: the new problems. Transplant Proc 1989;21(1 Pt 2):1440-5.
55. Kaplan CS, Petersen EA, Icenogle TB, Copeland JG, Villar HV, Sampliner R, et al. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients. Arch Intern Med 1989;149:2095-100.
56. Gangahar DM, Liggett SP, Casey J, Carveth SW, Reese HE, Buchman RJ, et al. Two episodes of cytomegalovirus-associated colon perforation after heart transplantation with successful result. J Heart Transplant 1988;7:377-9.
57. Shutze WP, Kirklin JK, Cummings OW, Aldrete JS. Cytomegalovirus hemorrhoiditis in cardiac allograft recipients. Transplantation 1991;51:918-20.
58. Bramwell NH, Davies RA, Koshal A, Tse GN, Keon WJ, Walley VM, et al. Fatal gastrointestinal hemorrhage caused by cytomegalovirus duodenitis and ulceration after heart transplantation. J Heart Transplant 1987;6:303-6.
59. Shuster LD, Cox G, Bhatia P, Miner PB Jr. Gastric mucosal nodules due to cytomegalovirus infection. Dig Dis Sci 1989; 34:103-7.
60. Pollard RB, Rand KH, Arvin AM, Merigan TC. Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis 1978;137:541-9.
61. Simmons RL, Matas AJ, Rattazzi LC, Balfour HH Jr, Howard JR, Najarian JS. Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation. Surgery 1977;82:537-46.
62. Jonsyn G, Radovančević B, Abou-Awdi NL, Patel V, Zeluff B, Frazier OH. Immunoglobulin plays a major role in antiviral prophylaxis in CMV mismatched cardiac transplant recipients. J Heart Lung Transplant 1995;14(1 Pt 2):S64.
63. Radovančević B, Frazier OH, Gentry LO, Okereke OUJ, Cooley DA. Successful treatment of invasive aspergillosis in a heart transplant patient. Tex Heart Inst J 1985;12:233-7.
64. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
65. Barr ML, Berger CL, Wiedermann JG, Murphy MP, Jorgensen BA, McLaughlin SN, et al. Photochemotherapy for the prevention of graft atherosclerosis in cardiac transplantation. J Heart Lung Transplant 1993;12(1 Pt 2):S85.
66. Patel VS, Radovančević B, Springer W, Frazier OH, Massin E, Benrey J, et al. Revascularization procedures in patients with transplant coronary artery disease. Eur J Cardiothorac Surg 1997;11:895-901.
67. Frazier OH, Kadipasaoglu KA, Radovančević B, Cihan HB, March RJ, Mirhoseini M, et al. Transmyocardial laser revascularization in allograft coronary artery disease. Ann Thorac Surg 1998;65:1138-41.
68. Cooley DA, Frazier OH, Kadipasaoglu KA, Pehlivanoglu S, Shannon RL, Angelini P. Transmyocardial laser revascularization. Anatomic evidence of long-term channel patency. Tex Heart Inst J 1994;21:220-4.
69. Nalesnik MA, Locker J, Jaffe R, Reyes J, Cooper M, Fung J, et al. Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clin Transplantation 1992;6:249-52.